Skip to content

    Stallion India Fluorochemicals Limited

    STALLION
    Chemicals·16 Oct 2025
    Management Summary

    Stallion India Fluorochemicals Ltd. reported robust Q2 and H1 FY26 results, with significant YoY growth in revenue, EBITDA, and PAT, exceeding 50% of its full-year revenue guidance. The company is making strategic progress on backward integration and capacity expansion with new facilities for R32 manufacturing and HFO refrigerants, despite a challenging macroeconomic environment and cyclical product markets. Management expressed confidence in achieving growth targets and expanding margins through these initiatives.

    Highlights

    5
    • Q2 FY26 revenue grew 55.6% YoY to INR 105.75 crores, driven by higher volumes, improved product mix, and strong demand.

    • Q2 FY26 EBITDA surged nearly seven-fold to INR 15.77 crores with margins expanding to 14.9%.

    • H1 FY26 revenue grew 52.8% YoY to INR 216.3 crores, with PAT increasing by 135% to INR 21.78 crores.

    • Achieved over 50% of full-year revenue guidance of INR 430 crores within the first half, demonstrating strong operational leverage.

    • Strategic progress on backward integration with new R32 manufacturing facility in Bhilwara and enhanced Mambattu facility for HFO refrigerants and specialty gases.

    Concerns

    3
    • Challenging macroeconomic backdrop characterized by global tariff-related headwinds and cyclical slowdown in certain sectors.

    • Helium is a cyclical product, with prices fluctuating significantly (e.g., INR 1,200 today vs. INR 4,800 three years ago).

    • R32 manufacturing capacity in India is currently in excess of domestic demand, making exports the profitable segment for this product.

    Key financials

    Metrics

    6

    Periods

    2

    Q2 FY26

    4
    • Revenue
      ₹105.75 Cr
      YoY+55.6%
    • EBITDA
      ₹15.77 Cr
      YoY+6%
    • EBITDA Margin
      14.9%
    • PAT
      ₹11.42 Cr

    H1 FY26

    2
    • Revenue
      ₹216.3 Cr
      YoY+52.8%
    • PAT
      ₹21.78 Cr
      YoY+135%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹50 crores

    Bhilwara project funded by internal accruals; enhanced Mambattu and Khalapur projects funded by internal accruals.

    Liquidity

    Liquidity disclosed

    Company has sufficient internal funds for smaller CapEx requirements like the Bhilwara project.

    Guidance & targets

    10
    CategoryTargetPriority
    Revenue
    Full-year Revenue
    INR 430 crores
    High
    Revenue
    CAGR Growth
    30-35%
    High
    Revenue
    Bhilwara Plant Revenue (Initial 6 months)
    INR 250 crores
    High
    Revenue
    Bhilwara Plant Revenue (Full Year)
    INR 500-700 crores
    High
    Revenue
    Helium Business Revenue (Initial Year)
    INR 50 crores
    High
    Revenue
    Mambattu Plant Revenue (Initial Year)
    INR 50 crores
    High
    Revenue
    Current Business Revenue
    INR 500 crores
    High
    Profitability
    Operating Margins Expansion
    3-4%
    High
    Profitability
    Bhilwara Plant PAT Margin
    24%
    High
    Profitability
    Helium Business PAT Margin
    16-18%
    High

    What to watch in Q3 FY26

    5

    Khalapur Plant Operationalization

    December end or January max
    CurrentConstruction almost over, fit-out starting
    TargetOperational

    Why it matters

    This plant is part of the IPO-outlined CapEx and will contribute to helium and semiconductor gases, impacting future revenue and margins.

    Basically, we would expect that by December end, we should be operational in the Khalapur facility.

    Risks & concerns

    5
    RiskSeverity

    Macroeconomic Headwinds

    Global tariff-related headwinds and cyclical slowdown in certain sectors.Management acknowledged

    medium

    Raw Material Supply Chain Dependence

    Potential for sanctions from Chinese government on raw material supply, though currently no issue, company is diversifying sources.Analyst acknowledged

    low

    Helium Price Cyclicality

    Helium prices are subject to cyclical downturns, but a diversified product portfolio helps balance this.Management acknowledged

    medium

    R32 Overcapacity in India

    Indian R32 manufacturing capacity exceeds domestic demand, necessitating a focus on exports for profitability.Management acknowledged

    medium

    Project Delays due to Natural Calamities

    Severe flooding at the Mambattu facility caused a three-month delay, but work has resumed and is on track.Management acknowledged

    low

    Q&A highlights

    8

    “Not currently. Currently, we're not manufacturing. But onwards, when we move into manufacturing, fluorospar would be one of the raw materials. We import from a mix of places. We import from Japan. We import from China. We import from Middle-East also now, and we import from the U.S. and Europe, it is a mix. We've been moving away. But to answer your question, the majority part, 80%, 85% of the fluorochemical industry operates from China. So directly, indirectly, you would be working with China.”

    Clarifies the company's current and future raw material strategy, including efforts to diversify away from China, which is a key supply chain risk.

    asked by Shreya Masalia

    3 min read6 chapters

    Detailed Narrative

    01

    Robust Q2 and H1 FY26 Performance

    Stallion India Fluorochemicals Ltd. delivered strong financial results for Q2 FY26, with total revenues reaching INR 105.75 crores, marking a 55.6% YoY growth. EBITDA surged nearly seven-fold to INR 15.77 crores, and PAT increased to INR 11.42 crores, with margins expanding to 14.9%. For the first half of FY26, total revenue was INR 216.3 crores (52.8% YoY growth), and PAT increased by 135% to INR 21.78 crores. The company has already achieved over 50% of its full-year revenue guidance of INR 430 crores.

    02

    Strategic Capacity Expansion and Backward Integration

    The company is aggressively pursuing backward integration and capacity expansion. The 10,000 metric ton R32 manufacturing facility in Bhilwara, Rajasthan, is under development with a minimum CapEx of INR 200 crores, aiming for operationalization within 9 months (by July 2026). The Mambattu facility in Andhra Pradesh, initially planned with INR 20 crores CapEx, has been enhanced 2.5 times to increase blending and debulking capacity for HFO refrigerants and specialty gases, targeting operationalization by January end. The Khalapur facility, with an IPO-outlined CapEx of INR 30 crores, is expected to be operational by December end or January max.

    03

    Entry into High-Purity Semiconductor Gases

    Stallion is expanding its Khalapur facility to strengthen its footprint in liquid helium and high-purity semiconductor gases, targeting India's emerging electronic, solar, and fiber optic industries. The company aims for 6N purity (99.999999%) helium, requiring specialized handling, testing capabilities, and cylinder conditioning. The approval process for semiconductor gases is rigorous, taking 2-3 years, but creates a significant competitive moat and pricing power once qualified. This move aligns with the Prime Minister's push for semiconductor self-reliance.

    04

    Refrigerant Quota System and Market Dynamics

    The upcoming refrigeration quota system (Kigali Accord) for 2028 will be based on baseline years (2024-2026) and will feature tradable quotas, guiding the industry towards lower Global Warming Potential (GWP) products like HFOs. While India's R32 manufacturing capacity currently exceeds domestic demand (16,000-18,000 metric tonnes demand vs. 30,000-40,000 tonnes capacity), the profitable segment is exports. Demand is expected to grow with the AC/refrigeration industry (15-20% YoY) and increasing use of R32 in HFO blends, with China's capacity reductions happening earlier than India's.

    05

    Margin Outlook and Cyclicality Management

    The company expects significant margin expansion with backward integration. The Bhilwara R32 plant is projected to achieve a PAT margin of 24%, and the helium business 16-18%. While current business margins are optimal, the new manufacturing activities are expected to drive overall profitability. Management acknowledges the cyclical nature of products like helium but aims to balance this through a diversified product portfolio across the fluorochemical range, ensuring steady growth and mitigating demand cyclicality in end-user industries.

    06

    Funding Strategy and Internal Accruals

    Stallion is funding its current expansion projects, including the Bhilwara R32 plant and the enhanced Mambattu and Khalapur facilities, primarily through internal accruals. Management emphasized that the company has sufficient funds from its current profitability (INR 40 crore PAT, INR 20 crore PAT) for these smaller requirements. They stated that they would approach the market for funding only when larger capital requirements, such as future AHF/MDC (INR 450-500 crores) or HFO (INR 500-700 crores) backward integration, arise.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.